Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan plus amlodipine for angiogenesis inhibitor–induced hypertension in cancer patients
jRCT1041240078Recruiting
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sacubitril + valsartan and amlodipine in hypertension (HTN) and cancer. Primary endpoint: Rate of blood pressure control. Started Dec 2024; status: recruiting.
02
Drugs
sacubitril + valsartanamlodipine
03
Conditions
hypertension (HTN)cancer
Beyond the preview
Go deeper on jRCT1041240078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041240078.